Collegium Pharmaceutical (COLL) Interest & Investment Income (2014 - 2026)

Collegium Pharmaceutical's Interest & Investment Income history runs 13 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• In Q1 2026, Interest & Investment Income rose 66.56% year-over-year to $3.7 million; the TTM figure through Mar 2026 stood at $12.8 million (up 9.01% YoY), while the FY2025 annual figure was $11.3 million, down 19.23% from the prior year.
• Interest & Investment Income was $3.7 million for Q1 2026 at Collegium Pharmaceutical, up from $3.6 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $4.5 million in Q3 2023 to a low of $4000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $2.7 million across 5 years, with a median of $3.1 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Interest & Investment Income soared 80440.0% in 2023, then tumbled 57.89% in 2024.
• A 5-year view of Interest & Investment Income shows it stood at $1.0 million in 2022, then soared by 318.99% to $4.3 million in 2023, then sank by 57.89% to $1.8 million in 2024, then soared by 96.74% to $3.6 million in 2025, then grew by 3.96% to $3.7 million in 2026.
• The last three Interest & Investment Income figures came in at $3.7 million (Q1 2026), $3.6 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.